Investing in Champions Oncology, Inc. (CSBR)  ➔  Intrinsic value

Prev. close$10.34 
ModelValueUpside
Chepakovich$12.75+23%
Graham-Dodd$0.66-94%
Graham$1.47-86%
Previous Close$10.34  
Valuation MethodValuePotential 
Chepakovich Model$12.75+23%recalculate
Graham-Dodd$0.66-94%recalculate
Graham Formula$1.47-86%recalculate

Latest news

Company description

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.